Ver todos los criterios de elegibilidad
Ver detalles del protocolo
Patients with Grade I soft tissue sarcomas or benign, non-metastasizing invasive soft tissue tumors will receive wide local excision and be prospectively randomized as to either receive or not receive radiation therapy. This is a randomized study. Patients undergo surgical excision of all gross disease and then are randomized to Arm I or Arm II. Arm I: Radiotherapy. Involved-field irradiation. Arm II: No further treatment.
DISEASE CHARACTERISTICS: Biopsy-proven grade I soft tissue sarcoma or one of the following benign but highly invasive soft tissue tumors: Abdominal and extra-abdominal fibromatosis (desmoid, aggressive fibromatosis), Dermatofibrosarcoma protuberans, Intramuscular lipoma (infiltrating lipoma), Diffuse lipomatosis, Leiomyoma of deep soft tissue, Diffuse giant cell tumor of tendon sheath (proliferative synovitis). No clinical evidence of metastases in regional nodes or more distant sites. No primary intraperitoneal or retroperitoneal tumors. Resection of all gross tumor at the time of surgical excision required (margins may be pathologically positive or negative). No von Recklinghausen's disease. PRIOR/CONCURRENT THERAPY: Biologic Therapy: Not specified. Chemotherapy: No prior chemotherapy for sarcoma. Endocrine Therapy: Not specified. Radiotherapy: No prior radiotherapy for sarcoma. Surgery: No more than 4 months since definitive surgery for primary lesion or recurrence. No prior amputation. PATIENT CHARACTERISTICS: Age: 18 and over. Performance status: Not specified. Hematopoietic: Not specified. Hepatic: No cirrhosis. Renal: No evidence of severe renal impairment. Cardiovascular: No ischemic heart disease. OTHER: No prior malignancy except basal cell carcinoma. No serious infection. No active bleeding disorder. No severe concomitant disease.